Related Experiment Video

Updated: Aug 19, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

Levamisole treatment of recurrent spastic bronchitis in children--the effect on selected parameters of immunologic

W Prusek, E Wieczorek, M Podwysocka

    Archivum Immunologiae Et Therapiae Experimentalis
    |January 1, 1985
    PubMed

    Insights

    Levamisole effectively treated spastic bronchitis in children, with most experiencing full recovery. Treatment also boosted T lymphocyte counts without significant side effects, indicating a promising therapeutic option.

    Area of Science:

    • Pediatric Pulmonology
    • Immunopharmacology

    Background:

    • Spastic bronchitis is a common respiratory condition in children.
    • Current treatments may have limitations or side effects.

    Purpose of the Study:

    • To evaluate the efficacy and safety of levamisole in treating pediatric spastic bronchitis.
    • To assess the impact of levamisole on immune parameters in affected children.

    Main Methods:

    • A cohort of 20 children diagnosed with spastic bronchitis received levamisole.
    • The medication was administered for 3 consecutive days over two weeks.
    • Clinical outcomes and peripheral T lymphocyte counts were monitored.

    Main Results:

    • Full therapeutic effect was observed in 16 out of 20 children.
    • Partial therapeutic effect was noted in 1 child.
    • Clinical improvement correlated with an increase in peripheral T lymphocyte numbers.
    • No significant adverse events were reported during the study.

    Conclusions:

    • Levamisole demonstrates significant efficacy in treating spastic bronchitis in children.
    • The observed increase in T lymphocytes suggests an immunomodulatory effect.
    • Levamisole appears to be a safe and well-tolerated treatment option for this condition.

    More Related Videos

    Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures03:07

    Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures

    Published on: July 12, 2024

    In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase05:55

    In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase

    Published on: April 4, 2025

    Related Concept Videos

    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    Antiasthma Drugs: Leukotriene Modifiers01:19

    Antiasthma Drugs: Leukotriene Modifiers

    Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
    Leukotriene modifiers work through two distinct mechanisms:
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    Respiratory Syncytial Virus Disease01:29

    Respiratory Syncytial Virus Disease

    Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
    Anthelminthic Agents01:15

    Anthelminthic Agents

    Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
    Antiprotozoal Agents01:21

    Antiprotozoal Agents

    Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...